KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.90

Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain : A Prospective, Randomized, Phase 3 Trial.

Peiyong Li, Yitian Chen, Yingyi Lin, Xiaoqi Zhang, Minyi Cheng, Teng Zhu, Hong-Fei Gao, Liulu Zhang, Jieqing Li, Na Huang, Yilin Chen, Minting Liang, Yuanqi Zhang, Shengchao Huang, Junqiu Zheng, Cangui Wu, Ciqiu Yang, Kun Wang

Ann Intern Med 179(5) 656-665

PMID41871353
PMCID-
DOI10.7326/ANNALS-25-02600
发表日期2026-03-23
入排依据:While this is a Phase III randomized oncology trial in humans, it reports only pain and neutropenia outcomes, not survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes required for inclusion in the KM cohort.
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Pegfilgrastim-induced bone pain (PIBP) is common and lacks effective treatment. OBJECTIVE: To determine whether there is an association between the timing of pegfilgrastim administration and PIBP. DESIGN: Three-arm randomized controlled trial. (ClinicalTrials.gov: NCT05841186). SETTING: A tertiary A-level hospital. PATIENTS: Patients with I to III stage breast cancer who were naive to chemotherapy. INTERVENTION: Patients were randomly allocated in a 1:1:1 ratio to the 24-hour, 48-hour, or 72-hour group based on the timing of pegfilgrastim administration postchemotherapy. MEASUREMENTS: The primary end point was the area under the curve (AUC) of the daily worst bone pain score (assessed using the "worst pain" question from the Brief Pain Inventory, a 0 to 10 numerical rating scale [NRS]) for 5 consecutive days in the first chemotherapy cycle. Secondary end points included the incidence of severe bone pain (>5 on the NRS), neutropenia, and febrile neutropenia (FN). RESULTS: The intention-to-treat analyses included 159 patients, with 53 in each group. For the first cycle, in the 72-hour group, the mean AUC exhibited a statistically significant reduction from 12.74 in the 24-hour group and 14.20 in the 48-hour group to 6.05 (all P < 0.001). Furthermore, the incidence of severe bone pain also declined significantly from 58.5% in the 24-hour group and 66.0% in the 48-hour group to 22.6% in the 72-hour group (all P < 0.001). There was no substantial difference in the incidence of neutropenia among groups, and no patients developed FN. LIMITATION: Open label, single center, and relatively small sample size. CONCLUSION: Administration of pegfilgrastim 72 hours postchemotherapy reduced PIBP compared with 24- and 48-hour administration and did not seem to be associated with higher rates of neutropenia or FN. PRIMARY FUNDING SOURCE: National Natural Science Foundation of China.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。